Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-013675
Filing Date
2022-08-15
Accepted
2022-08-15 17:59:43
Documents
57
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20220630x10q.htm   iXBRL 10-Q 1284186
2 EX-31.1 tmb-20220630xex31d1.htm EX-31.1 10599
3 EX-31.2 tmb-20220630xex31d2.htm EX-31.2 10447
4 EX-32.1 tmb-20220630xex32d1.htm EX-32.1 6676
5 EX-32.2 tmb-20220630xex32d2.htm EX-32.2 6353
  Complete submission text file 0001558370-22-013675.txt   5144911

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20220630.xsd EX-101.SCH 36484
7 EX-101.CAL tmb-20220630_cal.xml EX-101.CAL 34870
8 EX-101.DEF tmb-20220630_def.xml EX-101.DEF 145638
9 EX-101.LAB tmb-20220630_lab.xml EX-101.LAB 340429
10 EX-101.PRE tmb-20220630_pre.xml EX-101.PRE 251135
51 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20220630x10q_htm.xml XML 856044
Mailing Address 375 PHEASANT RUN NEWTOWN PA 18940
Business Address 375 PHEASANT RUN NEWTOWN PA 18940 267-759-3681
Onconova Therapeutics, Inc. (Filer) CIK: 0001130598 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36020 | Film No.: 221167319
SIC: 2834 Pharmaceutical Preparations